Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD
May 03, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the...
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
April 25, 2022 16:01 ET
|
Cognition Therapeutics, Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...